...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Volume

,,DMcC might as well have kept this company as a private entity,,,no sense in using the open market to aquire shares,,just ask any of the team,,,,and bonus out warrants,,,,,no wonder this share price is where it is,,,,,pitiable at best,,,,!,,,I dont remember of any other company in my time in the markets continually doing these distributions lending the open market aa a distant second choice. The very reason we are a public company!!!!!!!!!!!!!!!!!!!!!!

Share
New Message
Please login to post a reply